The University of Kansas Cancer Center Senior Leadership team is led by the Director, who is assisted by the Deputy Director, the Chief Operating Officer, and seven Associate Directors. The team meets bi-monthly, to discuss matters pertaining to the four research programs and their scientific progress;the four shared resources and their cost effectiveness, utilization, and quality;ad hoc budget requests from Cancer Center members;space allocation requests;new shared resources or shared equipment requests;and set all Cancer Center policies and procedures. The Senior Leaders also meet regularly in the context of the Cancer Center's Leadership Council (every other month). Program Leader (every other month) and/or Shared Resource meetings (quarterly). Collectively the Senior Leadership has ultimate responsibility for identifying, developing, and implementing intra- and inter-programmatic collaborative research opportunities. Each Senior Leader contributes a special expertise that collectively provides the Director counsel related to the development and growth of the Cancer Center's clinical trial portfolio, shared resources, basic, translational, clinical and population sciences, and research base and funding resources.
KUCC Senior Leadership provides the vision, direction, expertise, guidance, leadership and experience that is critical to the growth, development, and success of The University of Kansas Cancer Center.
| Gonzalez-Mercado, Velda J; Fridley, Brooke L; Saligan, Leorey N (2018) Sestrin family of genes and their role in cancer-related fatigue. Support Care Cancer 26:2071-2074 |
| Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620 |
| Roy, Anuradha (2018) Early Probe and Drug Discovery in Academia: A Minireview. High Throughput 7: |
| Lea, Wendy A; Parnell, Stephen C; Wallace, Darren P et al. (2018) Human-Specific Abnormal Alternative Splicing of Wild-Type PKD1 Induces Premature Termination of Polycystin-1. J Am Soc Nephrol 29:2482-2492 |
| Hirst, Jeff; Pathak, Harsh B; Hyter, Stephen et al. (2018) Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and Tumor Stem-like Properties. Cancer Res 78:4370-4385 |
| Trinca, Gloria M; Goodman, Merit L; Papachristou, Evangelia K et al. (2018) O-GlcNAc-Dependent Regulation of Progesterone Receptor Function in Breast Cancer. Horm Cancer 9:12-21 |
| Subramaniam, Dharmalingam; Kaushik, Gaurav; Dandawate, Prasad et al. (2018) Targeting Cancer Stem Cells for Chemoprevention of Pancreatic Cancer. Curr Med Chem 25:2585-2594 |
| Beadnell, Thomas C; Scheid, Adam D; Vivian, Carolyn J et al. (2018) Roles of the mitochondrial genetics in cancer metastasis: not to be ignored any longer. Cancer Metastasis Rev : |
| Li, Linda Xiaoyan; Zhou, Julie Xia; Calvet, James P et al. (2018) Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression. Cell Death Dis 9:326 |
| Peng, Weidan; Furuuchi, Narumi; Aslanukova, Ludmila et al. (2018) Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development. Mol Cell Biol 38: |
Showing the most recent 10 out of 177 publications
